Barchi J J, Marquez V E, Driscoll J S, Ford H, Mitsuya H, Shirasaka T, Aoki S, Kelley J A
Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
J Med Chem. 1991 May;34(5):1647-55. doi: 10.1021/jm00109a018.
Selected acid-stable (2'-fluoro-2',3'-dideoxyarabinofuranosyl)adenine nucleosides containing methyl groups and other lipophilic functions at various positions in the adenine ring were prepared and evaluated as anti-HIV agents. The N6-methyl (1f), N6-benzoyl (1g), and 6-chloro (1i) analogues had modest activity, giving 30-50% protection to ATH8 cells infected with HIV. 2-Methyl (1d), 8-methyl (1h), and 2,N6-dimethyl (1e) substitution, as well as N1-oxide (21) formation, abolished the activity of the parent compound (1a). Several of these compounds, originally designed as agents for treating HIV in the central nervous system, were further investigated as substrates for adenosine deaminase (ADA). Kinetic experiments showed that ADA catalyzed the formation of the anti-HIV active inosine compound 1b from the N6-methyl analogue 1f in a quantitative manner. The anti-HIV activity of 1f and 1i was abolished when the ADA inhibitor, 2'-deoxycoformycin, was added to the test mixture. In contrast, the activity of 1f was significantly enhanced when ADA was added to the test system. These data indicate that 1f and 1i are prodrug forms of 1b in systems containing ADA.
制备了在腺嘌呤环的不同位置含有甲基和其他亲脂性功能的选定酸稳定型(2'-氟-2',3'-二脱氧阿拉伯呋喃糖基)腺嘌呤核苷,并将其作为抗HIV药物进行评估。N6-甲基(1f)、N6-苯甲酰基(1g)和6-氯(1i)类似物具有适度的活性,能为感染HIV的ATH8细胞提供30-50%的保护。2-甲基(1d)、8-甲基(1h)和2,N6-二甲基(1e)取代以及N1-氧化物(21)的形成消除了母体化合物(1a)的活性。这些化合物中的几种最初被设计为治疗中枢神经系统HIV的药物,后来进一步作为腺苷脱氨酶(ADA)的底物进行研究。动力学实验表明,ADA能以定量方式催化从N6-甲基类似物1f形成抗HIV活性肌苷化合物1b。当向测试混合物中加入ADA抑制剂2'-脱氧助间型霉素时,1f和1i的抗HIV活性被消除。相反,当向测试系统中加入ADA时,1f的活性显著增强。这些数据表明,在含有ADA的系统中,1f和1i是1b的前药形式。